Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Louise Faaborg"'
Autor:
Nanna Brink Scholz, Lars Bolund, Mette Nyegaard, Louise Faaborg, Mette Warming Jørgensen, Helle Lund, Isa Niemann, Lone Sunde
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0142545 (2015)
Hydatidiform moles (HMs) are abnormal human pregnancies with vesicular chorionic villi, imposing two clinical challenges; miscarriage and a risk of gestational trophoblastic neoplasia (GTN). The parental type of most HMs are either diandric diploid (
Externí odkaz:
https://doaj.org/article/c6aaa703372c4fc38db86b784dee1150
Autor:
Louise Faaborg, Rikke Fredslund Andersen, Marianne Waldstrøm, Jon Røikjær Henriksen, Parvin Adimi, Anders Jakobsen, Karina Dahl Steffensen
Publikováno v:
Cancers; Volume 14; Issue 7; Pages: 1766
Faaborg, L, Andersen, R F, Waldstrøm, M, Henriksen, J R, Adimi, P, Jakobsen, A & Steffensen, K D 2022, ' Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer ', Cancers, vol. 14, no. 7, 1766 . https://doi.org/10.3390/cancers14071766
Faaborg, L, Andersen, R F, Waldstrøm, M, Henriksen, J R, Adimi, P, Jakobsen, A & Steffensen, K D 2022, ' Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer ', Cancers, vol. 14, no. 7, 1766 . https://doi.org/10.3390/cancers14071766
Methylated Homeobox A9 circulating tumor DNA (meth-HOXA9) has been suggested as a blood-based biomarker in epithelial ovarian cancer (EOC), although its prognostic significance remains unproven. The aim of the present study was to investigate the pro
Autor:
Caroline Brenner Thomsen, Amanda Dandanell Juul, Anna Cecilie Lefèvre, Christina Glismand Truelsen, Edina Dizdarevic, Heidi Ryssel, Ina Mathilde Kjær, Karen Lycke Wind, Louise Bach Callesen, Louise Faaborg Larsen, Malene Støchkel Frank, Rikke Fredslund Andersen, Karen‐Lise Garm Spindler, Anders Jakobsen
Publikováno v:
Brenner Thomsen, C, Dandanell Juul, A, Lefèvre, A C, Glismand Truelsen, C, Dizdarevic, E, Ryssel, H, Mathilde Kjær, I, Lycke Wind, K, Callesen, L B, Faaborg Larsen, L, Støchkel Frank, M, Fredslund Andersen, R, Garm Spindler, K L & Jakobsen, A 2022, ' Reporting on circulating tumor DNA monitoring in metastatic cancer—From clinical validity to clinical utility ', Cancer, vol. 128, no. 11, pp. 2052-2057 . https://doi.org/10.1002/cncr.34168
Brenner Thomsen, C, Dandanell Juul, A, Lefèvre, A C, Glismand Truelsen, C, Dizdarevic, E, Ryssel, H, Mathilde Kjær, I, Lycke Wind, K, Callesen, L B, Faaborg Larsen, L, Støchkel Frank, M, Fredslund Andersen, R, Garm Spindler, K L & Jakobsen, A 2022, ' Reporting on circulating tumor DNA monitoring in metastatic cancer : From clinical validity to clinical utility ', Cancer, vol. 128, no. 11, pp. 2052-2057 . https://doi.org/10.1002/cncr.34168
Brenner Thomsen, C, Dandanell Juul, A, Lefèvre, A C, Glismand Truelsen, C, Dizdarevic, E, Ryssel, H, Mathilde Kjær, I, Lycke Wind, K, Callesen, L B, Faaborg Larsen, L, Støchkel Frank, M, Fredslund Andersen, R, Garm Spindler, K L & Jakobsen, A 2022, ' Reporting on circulating tumor DNA monitoring in metastatic cancer : From clinical validity to clinical utility ', Cancer, vol. 128, no. 11, pp. 2052-2057 . https://doi.org/10.1002/cncr.34168
Publikováno v:
Cancers, Vol 14, Iss 852, p 852 (2022)
Wallin, E, Niemann, I, Faaborg, L, Fokdal, L & Joneborg, U 2022, ' Differences in Administration of Methotrexate and Impact on Outcome in Low-Risk Gestational Trophoblastic Neoplasia ', Cancers, vol. 14, no. 3, 852 . https://doi.org/10.3390/cancers14030852
Cancers; Volume 14; Issue 3; Pages: 852
Wallin, E, Niemann, I, Faaborg, L, Fokdal, L & Joneborg, U 2022, ' Differences in Administration of Methotrexate and Impact on Outcome in Low-Risk Gestational Trophoblastic Neoplasia ', Cancers, vol. 14, no. 3, 852 . https://doi.org/10.3390/cancers14030852
Cancers; Volume 14; Issue 3; Pages: 852
Methotrexate (MTX) is frequently used as first-line treatment for low-risk gestational trophoblastic neoplasia (GTN). Intravenous and intramuscular (im) routes of administration are the most common methods, although oral administration is used by som
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Anders Jakobsen, Parvin Adimi, Rikke Fredslund Andersen, Estrid Høgdall, Marianne Waldstrøm, Louise Faaborg, Claus Høgdall, Karina Dahl Steffensen
Publikováno v:
Faaborg, L, Fredslund Andersen, R, Waldstrøm, M, Høgdall, E, Høgdall, C, Adimi, P, Jakobsen, A & Dahl Steffensen, K 2021, ' Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement ', Clinica Chimica Acta, vol. 522, pp. 152-157 . https://doi.org/10.1016/j.cca.2021.08.020
DNA promoter methylation is an early event in tumorigenesis and holds promise as a valuable marker in ovarian cancer (OC). It can be measured using circulating tumor specific DNA (ctDNA) isolated from the bloodstream. Sensitivity, however, is a limit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e34b15fb4074064d01e263387fc1e07a
https://findresearcher.sdu.dk:8443/ws/files/191308804/Open_Access_Version.pdf
https://findresearcher.sdu.dk:8443/ws/files/191308804/Open_Access_Version.pdf
Autor:
Rikke Fredslund Andersen, Marianne Waldstrøm, Christina Braad Petersen, Karina Dahl Steffensen, Anders Jakobsen, Louise Faaborg
Publikováno v:
Faaborg, L, Jakobsen, A, Waldstrøm, M, Petersen, C B, Andersen, R F & Steffensen, K D 2021, ' HOXA9-methylated DNA as a diagnostic biomarker of ovarian malignancy ', Biomarkers in Medicine, vol. 15, no. 15, pp. 1309-1317 . https://doi.org/10.2217/bmm-2021-0144
Aim: In ovarian cancer, methylated HOXA9 (meth-HOXA9) has been proposed as a relevant biomarker, however, its role in the carcinogenic development remains unknown. This study aimed at evaluating meth-HOXA9 as a diagnostic biomarker in ovarian cancer.
Autor:
Lars Henrik Jensen, Sara W C Wen, Torben Hansen, Louise Faaborg, Karina Dahl Steffensen, Rikke Fredslund Andersen, Anders Jakobsen, Caroline Brenner Thomsen
Publikováno v:
Jakobsen, A, Andersen, R F, Hansen, T F, Jensen, L H, Faaborg, L, Steffensen, K D, Thomsen, C B & Wen, S W C 2021, ' Early ctDNA response to chemotherapy : A potential surrogate marker for overall survival ', European Journal of Cancer, vol. 149, pp. 128-133 . https://doi.org/10.1016/j.ejca.2021.03.006
Aim: The aim of the study was to compare ctDNA response rate and objective response rate as surrogate markers for overall survival (OS) in patients with metastatic cancer treated with chemotherapy. Methods: The study included 420 patients distributed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f0e2293e6bf116aa61b5f34b6b0ad28
https://findresearcher.sdu.dk:8443/ws/files/185245951/1_s2.0_S0959804921001544_main.pdf
https://findresearcher.sdu.dk:8443/ws/files/185245951/1_s2.0_S0959804921001544_main.pdf
Autor:
Karina Dahl Steffensen, Louise Faaborg, Rikke Fredslund Andersen, Anders Jakobsen, Parvin Adimi, Jon Roeikjaer Henriksen
Publikováno v:
E-Poster viewings.
Objectives Platinum-resistant ovarian cancer (OC) remains a challenge with few or no treatment options. Methylation of the HOXA9 gene has been found in plasma of patients with OC. It does not, however, occur in blood from healthy individuals. The aim
Publikováno v:
Comuth, W J, Faaborg, L, Henriksen, L Ø & Münster, A-M B 2018, ' Measurement of dabigatran : previously demonstrated Hemoclot® Thrombin Inhibitor assay reagent instability on Sysmex CS-2100i is no longer an issue ', Scandinavian Journal of Clinical & Laboratory Investigation, vol. 78, no. 1-2, pp. 149-152 . https://doi.org/10.1080/00365513.2017.1403037
Comuth, W, Faaborg, L, Henriksen, L Ø & Münster, A-M B 2017, ' Measurement of dabigatran: previously demonstrated Hemoclot® Thrombin Inhibitor assay reagent instability on Sysmex CS-2100i is no longer an issue ', Scandinavian Journal of Clinical & Laboratory Investigation, vol. 78, no. 1-2, pp. 149-152 . https://doi.org/10.1080/00365513.2017.1403037
Comuth, W, Faaborg, L, Henriksen, L Ø & Münster, A-M B 2017, ' Measurement of dabigatran: previously demonstrated Hemoclot® Thrombin Inhibitor assay reagent instability on Sysmex CS-2100i is no longer an issue ', Scandinavian Journal of Clinical & Laboratory Investigation, vol. 78, no. 1-2, pp. 149-152 . https://doi.org/10.1080/00365513.2017.1403037
The Hemoclot® Thrombin Inhibitor (HTI) assay has been recommended for measurement of dabigatran concentrations in specific clinical situations. Traditionally, reagents for biochemical assays are prepared from instructions found in the package insert
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d15a5e64d88f8147b0ad9ede8d8c836
https://portal.findresearcher.sdu.dk/da/publications/1d5efdf6-baa0-46bf-8183-53bd182585f6
https://portal.findresearcher.sdu.dk/da/publications/1d5efdf6-baa0-46bf-8183-53bd182585f6